Mishra V, Kesharwani P, Jain NK. siRNA nanotherapeutics: a Trojan horse approach against HIV.
Drug Discov Today 2014;
19:1913-20. [PMID:
25281591 DOI:
10.1016/j.drudis.2014.09.019]
[Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2014] [Revised: 08/07/2014] [Accepted: 09/23/2014] [Indexed: 01/19/2023]
Abstract
The concept of RNA interference (RNAi) is gaining popularity for the better management of various diseases, including HIV. Currently, the successful biomedical utilization of siRNA therapeutics is hampered, both in vivo and in vitro, mainly by the inherent inability of naked siRNA to cross the cell membrane. RNAi can potentially improve the weakness of current highly active antiretroviral therapy (HAART) by diminishing the chances of the appearance of antiHIV-resistant strains. Here, we discuss the nanocarrier-mediated delivery of siRNA delivery as well as highlighted the scope of siRNA-mediated gene-silencing technology for improved HIV treatment.
Collapse